Breast Cancer Clinical Trial
Official title:
A Randomized Controlled Double-blinded Study Comparing the Intraoperative Injection of Lymphatic Mapping Agents Tc 99m Tilmanocept to Tc 99m Filtered Sulfur Colloid in Breast Cancer Patients Undergoing Breast Conservation and Sentinel Lymph Node Biopsy
A randomized controlled double-blinded study comparing the intraoperative injection of lymphatic mapping agents Tc 99m tilmanocept to Tc 99m filtered sulfur colloid in breast cancer patients undergoing breast conservation and sentinel lymph node biopsy
This study is a double-blinded randomized control trial comparing tilmanocept to TSC as
intraoperative radiolabeled mapping agents in female patients with early stage breast cancer
undergoing partial mastectomy with SLNBx.
To secure this aim, patients who are schedule to undergo partial mastectomy and SLBx will be
consented and randomized (randomization table) into one of two experimental arms, tilmanocept
or TSC.
These patients will then undergo their scheduled partial mastectomy with SLNBx, with the
patient and surgeon blinded to the randomization result.
The respective radiotracers will both be delivered to the OR in the same delivery device and
volumes to continue to preserve anonymity of the material. Care will be taken to handle the
radiotracers along the standards and guidelines that are already in practice in Memorial
Health University Hospital's nuclear medicine department. Two intradermal injections of these
radiotracers will be delivered at 3 and 6 o'clock positions at the edge of the areola, after
induction of general anesthesia, allowing for less discomfort to the patient.
Methylene blue (5-10 ml) will also be injected in the subareolar space immediately afterwards
in all study patients, using a separate syringe, in accordance with the surgeon's current
standard practice.
Transcutaneous probing of the axilla measuring counts per second will be performed in 3
minute intervals after injection of the radiotracer. Incision in the axilla can, at the
earliest, be at 15 minutes, as this is the FDA approved earliest time for tilmanocept. At
this time, if the transcutaneous "hot spot" detected by the gamma detector probe is detected,
an incision for SLNBx will proceed. A hot spot is defined as an area of increased
radioactivity in the axilla with a fall-off in radioactive counts in adjacent tissue. If a
hot spot is not detected, transcutaneous probing will continue at 3 minute intervals until
this value is reached. In an effort to not prolong the anesthesia time, incision at 30
minutes will be performed even if a hot spot is not identified transcutaneously.
No changes will be made to the method of SLNBx for this study. As axillary lymph node
dissection is no longer the standard of care at the time of SLNBx in partial mastectomy, we
will continue the practice of sending the SLN for permanent sectioning, however this will be
at the surgeon's discretion. If at the time of surgery there are histologically metastatic
nodes or if a sentinel node cannot be identified, the surgeon can proceed to axillary lymph
node dissection at their discretion, however for the purposes of this study only SLN data
will be tracked (please see below for further information on data collection).
Description of method for SLNBx:
After the intradermal injection of tilmanocept or TSC and sub-areolar injection of methylene
blue, and the decision to proceed with SLNBx, the standard incision will be made in the
axilla overlying the area with the most counts per second per the gamma probe. The
subcutaneous tissues are then dissected to the clavipectoral fascia. The fascia is then
incised and the axilla is again probed with the gamma probe. Once a blue node or radioactive
node(s) is detected they are excised. A radioactive node will be defined as having counts per
second that are 10 times higher than surrounding tissue (background count). Once excised, an
"ex-vivo" count will be taken of the sentinel node(s) and recorded. If the background
radiation of the axilla is less than 10% the counts per second (cps) of the "hottest"
harvested sentinel lymph node, the search for radioactive sentinel nodes will be deemed
complete. If there is greater than 10% the counts per second remaining in the axilla, then
additional nodes will be identified and excised using the same methods until the background
radiation is less than 10% the counts per second of the hottest sentinel nodes removed.
Additional nodes which are blue but not radioactive will be excised, as will any clinically
suspicious nodes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |